Assessment of risk of variant creutzfeldt-Jakob disease (vCJD) from use of bovine heparin.

Yin HuangRichard A ForsheeDavid KeireSau LeeLuisa GregoriDavid M AsherCyrus BettBrian NilandScott A BrubakerSteven A AndersonHong Yang

Published in: Pharmacoepidemiology and drug safety (2020)

The model estimates the vCJD risk from use of heparin when appropriately manufactured from US or Canadian cattle is likely small. The model and conclusions should not be applied to other medicinal products manufactured using bovine-derived materials.

Keyphrases

venous thromboembolism
growth factor